Friday, July 10, 2026

Drug profile · INN

padeliporfin

padeliporfin (TOOKAD) is an FDA-listed pharmaceutical active ingredient.

EMA: approved Antineoplastic and immunomodulating agents (L01) L01XD07
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — padeliporfin
Class
Antineoplastic and immunomodulating agents (L01)
Route
Patents
0
Programs
2
Data quality
0.83

Quick answer

padeliporfin (TOOKAD) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN padeliporfin
Brand TOOKAD
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XD07

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. CLIN2001UCM301 Phase 3 · Steba Biotech · Low Grade Upper Tract Urothelial Cancer
  2. Oka strain varicella attenuated live vaccine Phase 3 · Chinese Academy of · Chickenpox Vaccines

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is padeliporfin?

padeliporfin (TOOKAD) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for padeliporfin?

TOOKAD is a marketed brand name for padeliporfin. Check FDA Drugs@FDA for the current US label holder and prescribing information.